Yissum - Research Development Company of the Hebrew University

Cannabinoid-based Bone Anabolic Treatment

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

HU-308, a synthetic cannabinoid has demonstrated in vivo anti-osteoporotic efficacy of agonist highly specific for CB2 that concomitantly restrains bone resorption and stimulates bone formation. HU-308 has no psychotropic or anti-annorexigenic activities and is orally bioavailable YZ 8Feb11-HU-433- (from project 2159) Integrated with this project (Fatty-acid-derived therapy for osteoporosis and other skeletal deficits deficits)
Project ID : 6-2006-229

Description of the technology

New and innovative aspects

HU-308, a synthetic cannabinoid has demonstrated in vivo anti-osteoporotic efficacy of agonist highly specific for CB2 that concomitantly restrains bone resorption and stimulates bone formation. HU-308 has no psychotropic or anti-annorexigenic activities and is orally bioavailable YZ 8Feb11-HU-433- (from project 2159) Integrated with this project (Fatty-acid-derived therapy for osteoporosis and other skeletal deficits deficits)Project ID : 6-2006-229

Cannabinoid agonist restrains bone resorption and stimulates bone formation

Categories

Bone formation, osteoporosis, fracture healing, endossseous implants agonist for peripheral cannabinoid receptor

Development Stage

In vivo proof of principle; expanded pre-clinical experiments

Patent Status

Patent portfolio at various stages (from provisional to granted patents_

Market Size

Currently, the osteoporosis, fracture healing and enhancement of endosseous implant anchorage drug market is worth $20.0 billion

Highlights

  • Osteoporosis is characterized by an imbalance between bone formation and resorption resulting in net bone loss and increased susceptibility to fractures. In addition, complications associated with bone fractures and anchorage of bone implants are increasing because of the increased life expectancy and associated increase in fracture incidence and and insufficient bone formation required to support the implants.
  • Most anti-osteoporotic drugs in clinical use, such as bisphosphonates, estrogen, and calcitonin are anti-resorptive and used mainly to prevent postmenopausal bone loss. Use of PTH(1-34), the only clinically approved bone anabolic agent, is restricted to two years, because of bone cancer risk. Enhancement of fracture healing and implant anchorage by bone anabolic agents gained limited clinical success, mainly because of their proteinous nature.
  • Signaling of the peripheral cannabinoid receptor (CB2) is involved in the regulation of bone remodelling, slowing down and rescueing bone loss

Our Innovation

  • A highly potent synthetic cannabinoid agonist, which is specific for CB2 and therefore not psychoactive. It inhibits bone resorption and stimulates bone formation.

Key Features

  • Attenuates and reverses bone loss: restores bone mass and architecture.
  • No psychotropic or anti-annorexigenic activities.
  • Development Milestones
  • Further development of this treatment for the osteoporosis indication involves the standard path, e.g., toxicology, mutagenesis, in vivo pharmacology, stability studies and clinical trials. Proof of concept is still required for the fracture healing and implant anchorage indictions.

The Opportunity

  • Osteoporosis is the most prevalent degenerative disease in developed countries. The number of patients is expected to increase to 50 million in 2015.
  • The global market for bisphosphonates, the most commonly prescribed class of drugs for the prevention and treatment of osteoporosis, is approaching $10 billion and is growing rapidly.
  • Complications associated with fracture healing and implant anchorage are extremely common in orthopaedic and dental surgery.

Project manager

Shoshana KeynanVP, Head of Business Development, Healthcare

Project researchers

Itai BabHUJI, Faculty of Dental MedicineBone laboratory

Raphael MechoulamHUJI, School of PharmacyMedicinal chemistry & Natural products

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Life Science & Biotechnology
  • small molecule

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.